THE RELATIONSHIP BETWEEN APOB AND APOA1 WITH INSULINEMIC STATUS IN PREDIABETIC SUBJECTS

Reaz Mohammad Mazumdar; Mohammad Razuanul Hoque; Suman Mohajan; Imran Khan; Md. Zahid Hassan; Md. Omar Faruque; Liaquat Ali; Md. Golam Kabir

doi:10.3329/brc.v9i1.63596

Authors

Reaz Mohammad Mazumdar Bangladesh Council of Scientific & Industrial Research (BCSIR), Dhaka, Bangladesh
Mohammad Razuanul Hoque Department of Biochemistry & Molecular Biology, University of Chittagong, Chattogram-4331, Bangladesh
Suman Mohajan Bangladesh Council of Scientific & Industrial Research (BCSIR), Dhaka, Bangladesh
Imran Khan BIRDEM, Dhaka, Bangladesh
Md. Zahid Hassan BIRDEM, Dhaka, Bangladesh
Md. Omar Faruque BIRDEM, Dhaka, Bangladesh
Liaquat Ali BIRDEM, Dhaka, Bangladesh
Md. Golam Kabir Department of Biochemistry & Molecular Biology, University of Chittagong, Chattogram-4331, Bangladesh

DOI:

https://doi.org/10.3329/brc.v9i1.63596

Keywords:

Apolipoprotein B, Apolipoprotein A1, ApoB-ApoA1 ratio, insulin, HOMA%B, HOMA%S

Abstract

The present study was mainly aimed at exploring the causal association of the atherogenic (ApoB) and antiatherogenic apolipoproteins (ApoA1) and their ratio in the basic defects of pancreatic β cell dysfunction and insulin resistance in type 2 Diabetes Mellitus (T2DM). An intermediate stage towards diabetes, the prediabetic stage, was chosen to explore the association. Following a standardized selection process, 131 subjects were purposefully recruited for the study, including 18 with impaired fasting glucose (IFG), 56 with impaired glucose tolerance (IGT), and 57 with type 2 diabetes (T2DM). Fifty-nine healthy subjects served as controls. Glucose, lipid and insulin were estimated by glucose-oxidase, enzymatic colorimetric assay and enzyme linked immunosorbent assay (ELISA) respectively. Serum ApoB and ApoA1 were estimated by immuno-nephelometric method. Appropriate statistical tools were used to calculate statistical differences using Statistical Package for Social studies (SPSS) for Windows V12. Absolute insulin (mIU) levels were significantly higher in the IGT and T2DM groups compared to controls (p 0.001 and p = 0.001, respectively). HOMA%B (mean±SD) was significantly lower in T2DM groups (p=<0.001) and higher in IGT compared to the controls although it is significantly lower in IFG compared to the controls but mean value is about 90%. HOMA%S was significantly lower in IGT and T2DM group (p=0.001 and 0.002 respectively). ApoA1 levels were significantly higher only in the T2DM group (p = 0.027), whereas ApoB levels were higher in both the IGT and T2DM groups (p = 0.026-0.001).. Neither ApoB nor ApoA1 showed any significant difference in the IFG group as compared to control. ApoB-ApoA1 ratio did not show significant difference among the groups. ApoB showed significant positive correlation with both fasting and postprandial glucose (p=0.006 and 0.040 respectively). In IGT group ApoB was positively correlated with absolute insulin (p=0.025) and HOMA%B (p=0.049) and negatively with HOMA%S (p=0.026). ApoB, but not ApoA1 or the ApoB and ApoA1 ratio, seem to have a causal association with insulin resistance, and elevation of ApoB is also modulated by obesity and atherogenic lipids.

References

Bjornholt JV, Erikssen G, Aaser E, (1999). Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care; 22: 45-49.

Chan DC, Bennet PHR, Watts GF. Dyslipidemia in visceral obesity: mechanisms, implications and therapy. Am J Cardiovasc Drugs 2004; 4: 227–46.

Coutinho M, Gerstein HC, Wang Y (1999). The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care; 22: 233-240.

Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC. Impaired glucose tolerance and fasting hyperglycemia have different characteristics. Diabet Med 2000; 17:433-440.

Decode Study Group (2001). Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med; 161: 397-405.

Festa A, D’Agostino R J, Hanley AJG, Karter AJ, Saad MF and Haffner SM. Difference in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance and impaired fasting glucose. Diabetes 2004; 53: 1549-1555.

Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of lowdenspy lipoprotein cholesterol in plasma, with the use of preparative centrifuge. Clin Chem 1972;18:499-502.

Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 44:1386-1391, 1995.

Hanfeld M, Koehler C, Fuecker k, Henkel K, Schaper F, Temelkova- Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolersnce and impaired fasting glucose. Diabetes Care 2003;26: 868-874.

Kabir MG, Mosaraf MH, Hassan SN, Hassan Z, Khan I, Nahar Q, Alauddin M, Faruque MO and Ali L (2008). Association of serum free IGF-1 and IGFBP-1 with insulin sensitivity in impaired glucose tolerance (IGT) and type 2 diabetic subjects. Diabetologia 51 (Suppl 1): S261.

Kim BJ, Hwang ST, Sung KC, Kim BS, Kang JH, Lee MH et al. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 2005; 51: 2257–63.

Liao D, Shofer JB, Boyko EJ (2001). Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diabetes Care; 24: 39-44.

Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006; 259: 437–46.

Peter H. Winocour, Samuel Kaluvya, Kaushik Ramaiya, Linda Brown, Jill P. Millar, Martyn arrer, et al Relation Between Insulinemia, Body Mass Index, and Lipoprotein Composition in Healthy, Nondiabetic Men and Women Arterioscler. Thromb. Vasc. Biol 1992;12;393-402.

Rahman MH, Hafizur RM, Huq F, Nahar Q, Tazib T, Khan AR, Ali L (2006). Insulin secretion and insulin sensitivity in subjects with IGR. Diabetologia 49: 451.

Schianca GPC, Rossi A, Sainaghi pp, Maduli E and Bartoli E. The significance of IFG versus IGT: Importance of Insulin Secretion and resistance. Diabetes care 2003; 26: 1333-1337.

Shefin SM, Hafizur RM, Islam NM, Hossain MM, Latif ZA, Akter S, Nahar Q, Islam S, Hassan K, Faruque MO, Ali L (2008). Insulin secretion and insulin sensitivity in first degree relatives of subjects with impaired glucose regulation. Diabetologia 51 (Suppl 1): S136.

Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A. et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in us non-diabetic subjects. European Heart Journal 2007; 28: 2637-2643.

Stewart MW, Humphriss DB, Mitcheson J, Webster J, Walker M, Laker MF. Lipoprotein composition and serum apolipoproteins in normoglycaemic first-degree relatives of noninsulin dependent diabetic patients. Atherosclerosis 1998; 139: 115–21.

Sung KC, Hwang ST. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis 2005; 189: 161–9.

Tripathy D, Carlsson M, Almgren P, Osomaa B, Raskinen M-R, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance. Lessons from the Botnia Study. Diabetes 2000;49:975-980.

Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/ or impaired glucose tolerance. Diabetes 1999; 48: 2197-2203.

Zhang P, Engelgau MM, Valdez R (2003). Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies. Diabetes Care; 26: 2536-2542.

Zunic G, Jelic-Ivanovic Z, Spasic S,Stojiljkovik A, Majkic-Singh N. Reference value for Apolipoproteins A-I and B in Healthy Subjects, by age. Clin Chem 1992;38:566-569.

Wood D, De Backer G, Faergeman O (1998). Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis; 140: 199-270.